Mankind Pharma files DRHP for Rs 7,500 crore IPO

By News - Team

September 16, 2022

Mankind Pharma, the medicine maker, known for Manforce Condoms and Prega News, has filed its draft red herring prospectus (DRHP) with request controller Sebi for an original public immolation on Friday. According to bankers, the size of the public offer is anticipated to be Rs7,500 crore.

The company’s original public immolation comprises an offer for the trade of 4 crore equity shares by the promoters and being investors.The offer for trade comprises up to 1 crore shares by protagonist Juneja family, up to 2 crore shares by Capital International, over to 99.65 lakh by Beige, and over to 50,000 equity shares by Link Investment Trust.

The ChrysCapital- backed institute of GIC NSE-4.72% of Singapore and CPP Investments owns 10% of Mankind, while Capital International owns another 11% stake. The company has hired JM Morgan, Citi, Jefferies, Axis, IIFL, and Kotak as investment bankers.The establishment posted profit of about Rs8,000 crore and EBITDA of Rs2,200 crore in FY22.

Mankind’s top over-the-counter (OTC) brands include gestation testing tackle Prega News, exigency contraception Unwanted- 21, AcneStaranti-bacterial gel, Ringoutanti-fungal greasepaint, Gas- O-Fast, Kaloree 1 artificial sweetener, Heal- O-Kindanti-bacterial ointment, Dependence Deodorant, and KabzEnd.

This will be one of the largest public issues by a domestic medicine manufacturer after the Rs6,480-crore IPO of Gland Pharma NSE-1.13% in 2020. Macleods Pharmaceuticals has also filed to raise Rs5,000-crore through an original public immolation( IPO), while Pune- grounded Emcure Pharma is planning a Rs4,500-crore IPO.

About Mankind Pharma

Incorporated in 1991, we are India’s fourth largest pharmaceutical company in terms of domestic sales and are engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

We operate at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices, and have an established track record of building and scaling brands in-house.

Brand

Our efforts to establish “Mankind” as a well-recognized brand in India, our established market presence and experience in manufacturing quality products across various therapeutic areas have helped us to build and scale large brands. 18 brands out of our 20 highest selling brands are ranked among the three highest selling brands in their respective molecule groups and 18 of our brands are among the 300 highest selling brands of the IPM (source : IQVIA, FY 2022)

Products

In our domestic pharmaceuticals business, our products portfolio comprises a broad range of formulations across various acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients/ and respiratory.

Some of our highest selling pharmaceutical brands: